Key terms
About DYAI
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DYAI news
Mar 28
4:23pm ET
Dyadic International Announces Key Leadership Changes
Mar 28
8:42am ET
Dyadic International appoints Lucy as Chairman of board, changes to the board
Mar 21
8:36am ET
Dyadic International to showcase Dapibus system at Future Food Tech event
Feb 28
8:34am ET
Dyadic International enters strategic partnerhsip agreement with Rabian
Feb 21
8:35am ET
Dyadic International advances collaboration with IIBR
Feb 06
8:40am ET
Dyadic International announces research, development collab agreement
No recent news articles are available for DYAI
No recent press releases are available for DYAI
DYAI Financials
Key terms
Ad Feedback
DYAI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DYAI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
